Structured Review

Roche qualitative hcv rna
Preferences for <t>HCV</t> testing strategy. Half of respondents consider two-step testing strategy (see Figure 1 ) to be an optimal future testing approach in LMIC, while the other half prefer currently used two-step approach a . If one-step testing strategy is implemented, more than a half of respondents prefer to use HCV <t>RNA</t> test b
Qualitative Hcv Rna, supplied by Roche, used in various techniques. Bioz Stars score: 89/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/qualitative hcv rna/product/Roche
Average 89 stars, based on 7 article reviews
Price from $9.99 to $1999.99
qualitative hcv rna - by Bioz Stars, 2020-05
89/100 stars

Images

1) Product Images from "Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile"

Article Title: Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile

Journal: BMC Infectious Diseases

doi: 10.1186/s12879-017-2770-5

Preferences for HCV testing strategy. Half of respondents consider two-step testing strategy (see Figure 1 ) to be an optimal future testing approach in LMIC, while the other half prefer currently used two-step approach a . If one-step testing strategy is implemented, more than a half of respondents prefer to use HCV RNA test b
Figure Legend Snippet: Preferences for HCV testing strategy. Half of respondents consider two-step testing strategy (see Figure 1 ) to be an optimal future testing approach in LMIC, while the other half prefer currently used two-step approach a . If one-step testing strategy is implemented, more than a half of respondents prefer to use HCV RNA test b

Techniques Used:

Information about respondents. Professional profiles of 36 respondents to the HCV RNA and cAg TPPs
Figure Legend Snippet: Information about respondents. Professional profiles of 36 respondents to the HCV RNA and cAg TPPs

Techniques Used:

Preferred sensitivity and acceptable trade-offs between sensitivity and price. Over 50% of respondents see current price of HBV DNA, HCV RNA, and to a lesser extent HCV cAg, is seen as a major barrier to scale up the testing a . Half of respondents consider that 95% as an acceptable diagnostic sensitivity for a one-step diagnostic test whereas 43% prefer 98% b . Respondents were willing to pay more for a higher sensitivity and were willing to compromise on sensitivity for a cheap test c and d
Figure Legend Snippet: Preferred sensitivity and acceptable trade-offs between sensitivity and price. Over 50% of respondents see current price of HBV DNA, HCV RNA, and to a lesser extent HCV cAg, is seen as a major barrier to scale up the testing a . Half of respondents consider that 95% as an acceptable diagnostic sensitivity for a one-step diagnostic test whereas 43% prefer 98% b . Respondents were willing to pay more for a higher sensitivity and were willing to compromise on sensitivity for a cheap test c and d

Techniques Used: Diagnostic Assay

Preference for the HCV diagnostic test and the test of cure to be the same or different. Almost half of respondents preferred that the diagnostic test and test of cure be the same and about two thirds of these preferred that it be a decentralized (i.e. near-patient) HCV RNA test
Figure Legend Snippet: Preference for the HCV diagnostic test and the test of cure to be the same or different. Almost half of respondents preferred that the diagnostic test and test of cure be the same and about two thirds of these preferred that it be a decentralized (i.e. near-patient) HCV RNA test

Techniques Used: Diagnostic Assay

2) Product Images from "The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents Chronic Hepatitis C"

Article Title: The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents Chronic Hepatitis C

Journal: Gastroenterology

doi: 10.1053/j.gastro.2010.10.047

Mean Log 10 HCV RNA levels during the first 24 weeks of treatment by time on study (weeks) and treatment group
Figure Legend Snippet: Mean Log 10 HCV RNA levels during the first 24 weeks of treatment by time on study (weeks) and treatment group

Techniques Used:

3) Product Images from "Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection"

Article Title: Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection

Journal: Hepatology (Baltimore, Md.)

doi: 10.1002/hep.26263

Longitudinal measurement of HCV RNA, plasma IP-10 and ALT levels among individuals with A) Spontaneous clearance; B) Spontaneous clearance and subsequent reinfection; C) Persistent HCV infection; D) Persistent HCV infection and subsequent superinfection.
Figure Legend Snippet: Longitudinal measurement of HCV RNA, plasma IP-10 and ALT levels among individuals with A) Spontaneous clearance; B) Spontaneous clearance and subsequent reinfection; C) Persistent HCV infection; D) Persistent HCV infection and subsequent superinfection.

Techniques Used: Infection

Plasma IP-10 levels at acute HCV detection among HCV RNA positive participants with available IP-10 levels stratified by A) HCV RNA level at acute HCV detection (n=181 with available quantititive HCV RNA); B) HIV infection (n=215); C) rs8099917 IL28B
Figure Legend Snippet: Plasma IP-10 levels at acute HCV detection among HCV RNA positive participants with available IP-10 levels stratified by A) HCV RNA level at acute HCV detection (n=181 with available quantititive HCV RNA); B) HIV infection (n=215); C) rs8099917 IL28B

Techniques Used: Infection

Association between plasma IP-10 levels at acute HCV detection and spontaneous clearance among HCV RNA positive participants with available IP-10 levels and excluding treated individuals with an estimated duration of infection
Figure Legend Snippet: Association between plasma IP-10 levels at acute HCV detection and spontaneous clearance among HCV RNA positive participants with available IP-10 levels and excluding treated individuals with an estimated duration of infection

Techniques Used: Infection

4) Product Images from "Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study"

Article Title: Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study

Journal: PLoS ONE

doi: 10.1371/journal.pone.0122232

Distribution of sex, HCV genotype, IFNL3 genotype and peak HCV RNA levels by patterns of HCV RNA levels in individuals with acute HCV infection in the InC 3 study. (A) Sex, P = 0.09; (B) HCV genotype, P = 0.18; (C) IFNL3 genotype, P
Figure Legend Snippet: Distribution of sex, HCV genotype, IFNL3 genotype and peak HCV RNA levels by patterns of HCV RNA levels in individuals with acute HCV infection in the InC 3 study. (A) Sex, P = 0.09; (B) HCV genotype, P = 0.18; (C) IFNL3 genotype, P

Techniques Used: Infection

Patterns of HCV RNA levels in individuals with well-characterized acute HCV infection in the InC 3 study (total n = 162). (A) Monthly medians of HCV RNA levels, table underneath represents number of participants with available HCV RNA level measurements at each time point; (B) Fitted HCV RNA patterns, shaded areas represent the 95% confidence intervals.
Figure Legend Snippet: Patterns of HCV RNA levels in individuals with well-characterized acute HCV infection in the InC 3 study (total n = 162). (A) Monthly medians of HCV RNA levels, table underneath represents number of participants with available HCV RNA level measurements at each time point; (B) Fitted HCV RNA patterns, shaded areas represent the 95% confidence intervals.

Techniques Used: Infection

Monthly medians of HCV RNA and ALT levels in individuals with acute HCV infection in the InC 3 study (total n = 643). (A) HCV RNA levels, by infection outcome (clearance vs. persistence); (B) ALT levels by infection outcome (clearance vs. persistence), tables underneath panel A and B represent number of participants with available HCV RNA/ALT levels measurements at each time point; (C) Fitted HCV RNA patterns, shaded areas in panel C represent the 95% confidence intervals.
Figure Legend Snippet: Monthly medians of HCV RNA and ALT levels in individuals with acute HCV infection in the InC 3 study (total n = 643). (A) HCV RNA levels, by infection outcome (clearance vs. persistence); (B) ALT levels by infection outcome (clearance vs. persistence), tables underneath panel A and B represent number of participants with available HCV RNA/ALT levels measurements at each time point; (C) Fitted HCV RNA patterns, shaded areas in panel C represent the 95% confidence intervals.

Techniques Used: Infection

5) Product Images from "Factors associated with hepatitis C virus RNA levels in early chronic infection: The InC3 Study"

Article Title: Factors associated with hepatitis C virus RNA levels in early chronic infection: The InC3 Study

Journal: Journal of viral hepatitis

doi: 10.1111/jvh.12384

Distribution of HCV RNA levels during months 8-16 following infection, stratified by IFNL4 rs12979860 genotype, sex, HCV genotype, and HIV infection status in participants with acute HCV infection in the InC 3 study. (A) Stratified by IFNL4 rs12979860
Figure Legend Snippet: Distribution of HCV RNA levels during months 8-16 following infection, stratified by IFNL4 rs12979860 genotype, sex, HCV genotype, and HIV infection status in participants with acute HCV infection in the InC 3 study. (A) Stratified by IFNL4 rs12979860

Techniques Used: Infection

HCV RNA levels in early chronic infection
Figure Legend Snippet: HCV RNA levels in early chronic infection

Techniques Used: Infection

HCV RNA levels in early chronic infection
Figure Legend Snippet: HCV RNA levels in early chronic infection

Techniques Used: Infection

Overview of InC 3 study population and participants with persistent HCV infection and a detectable HCV RNA in early chronic infection (i.e. between months 8-16 post-infection)
Figure Legend Snippet: Overview of InC 3 study population and participants with persistent HCV infection and a detectable HCV RNA in early chronic infection (i.e. between months 8-16 post-infection)

Techniques Used: Infection

6) Product Images from "Assessment, by Transcription-Mediated Amplification, of Virologic Response in Patients with Chronic Hepatitis C Virus Treated with Peginterferon ?-2a"

Article Title: Assessment, by Transcription-Mediated Amplification, of Virologic Response in Patients with Chronic Hepatitis C Virus Treated with Peginterferon ?-2a

Journal: Journal of Clinical Microbiology

doi: 10.1128/JCM.39.8.2850-2855.2001

ALT levels of sustained virologic responders, virologic relapse patients, and nonresponders measured during baseline (before initiation of therapy), end-of-treatment (ETR, week 48), and end-of-follow-up (EFU, week 72) visits. Horizontal bars indicate median values of the cohorts. Dotted lines indicate the upper limit of normal of ALT levels for men (43 U/liter) and women (34 U/liter). Open circles in the panel of virologic relapse patients at the end of treatment (ETR) indicate patients who had HCV RNA detectable by the TMA-based assay (VERSANT HCV RNA Qualitative Assay).
Figure Legend Snippet: ALT levels of sustained virologic responders, virologic relapse patients, and nonresponders measured during baseline (before initiation of therapy), end-of-treatment (ETR, week 48), and end-of-follow-up (EFU, week 72) visits. Horizontal bars indicate median values of the cohorts. Dotted lines indicate the upper limit of normal of ALT levels for men (43 U/liter) and women (34 U/liter). Open circles in the panel of virologic relapse patients at the end of treatment (ETR) indicate patients who had HCV RNA detectable by the TMA-based assay (VERSANT HCV RNA Qualitative Assay).

Techniques Used:

Related Articles

Polymerase Chain Reaction:

Article Title: The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents Chronic Hepatitis C
Article Snippet: .. At baseline and weeks 24, 48, and 72, qualitative HCV RNA was assessed with Roche Cobas Amplicor HCV Qualitative PCR, v2.0 with a lower limit of detection of 60 IU/mL. ..

Amplification:

Article Title: Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study
Article Snippet: .. Qualitative HCV RNA testing was performed using the following assays: Versant TMA [Bayer, Australia; < 10 IU/ml], COBAS AmpliPrep/COBAS TaqMan (Roche, Branchburg, NJ, USA; < 15 IU/ml), COBAS AMPLICOR HCV Test v2.0 (Roche Diagnostics, Mannheim, Germany; < 50 IU/ml) or discriminatory HCV transcription-mediated amplification component of the Procleix HIV-1/HCV (Gen-Probe, San Diego, CA, USA; < 12 copies/mL). .. Quantitative HCV RNA testing was performed using the Versant HCV RNA 3.0 (Bayer, Australia; < 615 IU/ml), COBAS AMPLICOR HCV MONITOR 2.0 (Roche Diagnostics, Mannheim, Germany; < 600 IU/ml), COBAS AmpliPrep/COBAS TaqMan (Roche, Branchburg, NJ, USA; < 15 IU/ml) or an in-house PCR ( < 1000 IU/ml) [ , ].

Article Title: Factors associated with hepatitis C virus RNA levels in early chronic infection: The InC3 Study
Article Snippet: .. Qualitative HCV RNA testing was performed using the following assays: Versant TMA [Bayer, Australia; < 10 IU/ml], COBAS AmpliPrep/COBAS TaqMan (Roche, Branchburg, NJ, USA; < 15 IU/ml), COBAS AMPLICOR HCV Test v2.0 (Roche Diagnostics, Mannheim, Germany; < 50 IU/ml) or discriminatory HCV transcription-mediated amplification component of the Procleix HIV-1/HCV (Gen-Probe, San Diego, CA, USA; < 12 copies/mL). .. Quantitative HCV RNA testing was performed using the Versant HCV RNA 3.0 (Bayer, Australia; < 615 IU/ml), COBAS AMPLICOR HCV MONITOR 2.0 (Roche Diagnostics, Mannheim, Germany; < 600 IU/ml), COBAS AmpliPrep/COBAS TaqMan (Roche, Branchburg, NJ, USA; < 15 IU/ml) or an in-house PCR ( < 1000 IU/ml) ( , ).

Article Title: The effects of female sex, viral genotype and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection
Article Snippet: .. Qualitative HCV RNA testing was performed using the following assays: Versant TMA [Bayer, Australia; < 10 IU/ml], COBAS AmpliPrep/COBAS TaqMan (Roche, Branchburg, NJ, USA; < 15 IU/ml), COBAS AMPLICOR HCV Test v2.0 (Roche Diagnostics, Mannheim, Germany; < 50 IU/ml) or discriminatory HCV transcription-mediated amplification component of the Procleix HIV-1/HCV (Gen-Probe, San Diego, CA, USA; < 12 copies/mL). .. Quantitative HCV RNA testing was performed using the Versant HCV RNA 3.0 (Bayer, Australia; < 615 IU/ml), COBAS AMPLICOR HCV MONITOR 2.0 (Roche Diagnostics, Mannheim, Germany; < 600 IU/ml), COBAS AmpliPrep/COBAS TaqMan (Roche, Branchburg, NJ, USA; < 15 IU/ml) or an in-house PCR ( < 1000 IU/ml) ( , ).

other:

Article Title: Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection
Article Snippet: Qualitative HCV RNA testing was performed using the Versant TMA assay [Bayer, Australia; < 10 IU/ml;ATAHC], COBAS AmpliPrep/COBAS TaqMan HCV assay (Roche, Branchburg, NJ, USA; < 15 IU/ml;HITS-p) or COBAS AMPLICOR HCV Test v2.0 (Roche Diagnostics, Mannheim, Germany; < 50 IU/ml;HEPCO).

Aptima HCV Quant Dx Assay:

Article Title: Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile
Article Snippet: .. Currently available commercial quantitative and qualitative HCV RNA or HCV cAg assays are focused on centralized laboratory infrastructure (e.g. Roche COBAS Taqman HCV assay, Abbott RealTime HCV assay, Hologic Aptima® HCV Quant Dx Assay) [ ]. ..

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 89
    Roche qualitative hcv rna
    Preferences for <t>HCV</t> testing strategy. Half of respondents consider two-step testing strategy (see Figure 1 ) to be an optimal future testing approach in LMIC, while the other half prefer currently used two-step approach a . If one-step testing strategy is implemented, more than a half of respondents prefer to use HCV <t>RNA</t> test b
    Qualitative Hcv Rna, supplied by Roche, used in various techniques. Bioz Stars score: 89/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/qualitative hcv rna/product/Roche
    Average 89 stars, based on 7 article reviews
    Price from $9.99 to $1999.99
    qualitative hcv rna - by Bioz Stars, 2020-05
    89/100 stars
      Buy from Supplier

    Image Search Results


    Preferences for HCV testing strategy. Half of respondents consider two-step testing strategy (see Figure 1 ) to be an optimal future testing approach in LMIC, while the other half prefer currently used two-step approach a . If one-step testing strategy is implemented, more than a half of respondents prefer to use HCV RNA test b

    Journal: BMC Infectious Diseases

    Article Title: Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile

    doi: 10.1186/s12879-017-2770-5

    Figure Lengend Snippet: Preferences for HCV testing strategy. Half of respondents consider two-step testing strategy (see Figure 1 ) to be an optimal future testing approach in LMIC, while the other half prefer currently used two-step approach a . If one-step testing strategy is implemented, more than a half of respondents prefer to use HCV RNA test b

    Article Snippet: Currently available commercial quantitative and qualitative HCV RNA or HCV cAg assays are focused on centralized laboratory infrastructure (e.g. Roche COBAS Taqman HCV assay, Abbott RealTime HCV assay, Hologic Aptima® HCV Quant Dx Assay) [ ].

    Techniques:

    Information about respondents. Professional profiles of 36 respondents to the HCV RNA and cAg TPPs

    Journal: BMC Infectious Diseases

    Article Title: Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile

    doi: 10.1186/s12879-017-2770-5

    Figure Lengend Snippet: Information about respondents. Professional profiles of 36 respondents to the HCV RNA and cAg TPPs

    Article Snippet: Currently available commercial quantitative and qualitative HCV RNA or HCV cAg assays are focused on centralized laboratory infrastructure (e.g. Roche COBAS Taqman HCV assay, Abbott RealTime HCV assay, Hologic Aptima® HCV Quant Dx Assay) [ ].

    Techniques:

    Preferred sensitivity and acceptable trade-offs between sensitivity and price. Over 50% of respondents see current price of HBV DNA, HCV RNA, and to a lesser extent HCV cAg, is seen as a major barrier to scale up the testing a . Half of respondents consider that 95% as an acceptable diagnostic sensitivity for a one-step diagnostic test whereas 43% prefer 98% b . Respondents were willing to pay more for a higher sensitivity and were willing to compromise on sensitivity for a cheap test c and d

    Journal: BMC Infectious Diseases

    Article Title: Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile

    doi: 10.1186/s12879-017-2770-5

    Figure Lengend Snippet: Preferred sensitivity and acceptable trade-offs between sensitivity and price. Over 50% of respondents see current price of HBV DNA, HCV RNA, and to a lesser extent HCV cAg, is seen as a major barrier to scale up the testing a . Half of respondents consider that 95% as an acceptable diagnostic sensitivity for a one-step diagnostic test whereas 43% prefer 98% b . Respondents were willing to pay more for a higher sensitivity and were willing to compromise on sensitivity for a cheap test c and d

    Article Snippet: Currently available commercial quantitative and qualitative HCV RNA or HCV cAg assays are focused on centralized laboratory infrastructure (e.g. Roche COBAS Taqman HCV assay, Abbott RealTime HCV assay, Hologic Aptima® HCV Quant Dx Assay) [ ].

    Techniques: Diagnostic Assay

    Preference for the HCV diagnostic test and the test of cure to be the same or different. Almost half of respondents preferred that the diagnostic test and test of cure be the same and about two thirds of these preferred that it be a decentralized (i.e. near-patient) HCV RNA test

    Journal: BMC Infectious Diseases

    Article Title: Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile

    doi: 10.1186/s12879-017-2770-5

    Figure Lengend Snippet: Preference for the HCV diagnostic test and the test of cure to be the same or different. Almost half of respondents preferred that the diagnostic test and test of cure be the same and about two thirds of these preferred that it be a decentralized (i.e. near-patient) HCV RNA test

    Article Snippet: Currently available commercial quantitative and qualitative HCV RNA or HCV cAg assays are focused on centralized laboratory infrastructure (e.g. Roche COBAS Taqman HCV assay, Abbott RealTime HCV assay, Hologic Aptima® HCV Quant Dx Assay) [ ].

    Techniques: Diagnostic Assay